Review of the literature suggested recurrence of these findings, uncovering 9p24 gains containing JAK2, CD274 and PDCD1LG2 in 2/10 ANKL and 1/27 NKTCL patients, as well as 17q21.2 gains containing STAT3, STAT5A, and STAT5B in 1/10 ANKL and 3/17 NKTCL cases5 (Fig. 2e). This evidence concerns the gene JAK2 and extranodal nasal NK/T cell lymphoma.